Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...
Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...
Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks. On January 13, 2026, an announcement came regarding the Ro and Amgen Inc. (NASDAQ:AMGN) collaboration. Ro, a U.S. telehealth ...
On January 30, 2026, Amgen Inc. and Kyowa Kirin Co., Ltd. agreed to terminate their June 1, 2021 License and Collaboration Agreement under a newly executed Termination Agreement, with the termination ...
Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.
Monday - Friday, 6:00 - 7:00 PM ET Amgen CEO Bob Bradway told CNBC's Jim Cramer that a new trial showed his company's drug can reduce the risk of heart attack. "This trial answered questions that have ...
9d
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy?
Sagebrush Health Services has filed a lawsuit in California state court accusing Amgen of unlawfully cutting off 340B discounted drug sales to its Nevada clinics and reclaiming at least US$7,000,000 ...
Monday - Friday, 6:00 - 7:00 PM ET Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients maintain weight loss, which he indicated is a challenge. "We ...
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's ...
CEO Robert Bradway stated that "Amgen delivered another strong quarter, driven by rising demand for our medicines and meaningful progress across the pipeline. Volume growth once again paced our ...
Amgen Inc (AMGN) reached a significant milestone as its stock hit a 52-week high of $346.41. This marks a notable point for the biotechnology company, reflecting a positive trend over the past year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results